COVID-19: cardiovascular manifestations—a review of the cardiac effects

Taha Hatab, Mohamad Bahij Moumneh, Abdul Rahman Akkawi, Mohamad Ghazal, Samir E. Alam, Marwan M. Refaat

Department of Internal Medicine, Division of Cardiology, American University of Beirut Medical Center, Beirut, Lebanon
Correspondence to: salam@aub.edu.lb; mr48@aub.edu.lb
https://doi.org/10.11909/j.issn.1671-5411.2022.03.007

The coronavirus first reported in China in November 2002 in the form of atypical pneumonia known as the severe acute respiratory syndrome (SARS) [1]. The virus then appeared in 2012 in Saudi Arabia as the Middle East respiratory syndrome (MERS) [2]. The year 2020 witnessed a novel β-coronavirus related to the previous detected viruses [3]. It was the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) — a positive single stranded RNA virus. It was suspected that bats were the main reservoir, leading to speculation about possible animal to human transmission [4,5]. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has already infected over 450 million people worldwide and has killed more than 6 millions. The pandemic strained the emergency medical services in many countries and led to an increased mortality [6]. Researchers stated that the virus can spread from large respiratory droplets on contaminated surfaces, aerosol transmission of small respiratory droplets and from symptomatic, asymptomatic and pre-symptomatic patients [7]. The WHO declared the COVID-19 as a pandemic on March 11, 2020 [8].

Coronaviruses are named after the spikes on their surface which form a crownlike dome, and they are known to cause respiratory infections in humans and animals [9]. SARS-CoV-2, in particular, clinical pattern progresses from an early infection (Stage I), pulmonary phase (Stage II) to hyperinflammation (Stage III) and can be lethal [10]. This has created multiple challenges since acute respiratory infections are one of the known triggers for cardiovascular diseases (CVD) [11] and the presence of CVD may complicate and worsen the course of the infectious disease [12]. COVID-19 binds via its spike protein the Spike protein receptor-binding domain to the zinc peptidase angiotensin-converting enzyme 2 (ACE2), which acts as a receptor for the virus [13]. ACE2 is a surface molecule found on vascular endothelial cells, arterial smooth muscle, and cardiac myocytes [14,15]. When COVID-19 attaches to ACE2 receptors on myocardial cells, it causes their down regulation as well as imbalance of Angiotensin II (AII) and Angiotensin 1-7 (A1-7) which is generated by ACE2; unbalanced AII activity leads to endothelial injury, inflammation exacerbation and known thrombotic consequences seen in COVID-19 in addition to the inflammatory pathways provoked by lung viral invasion [16-19]. It is well established that COVID-19 has many systemic and respiratory manifestations, including major severe cardiovascular consequences. COVID-19 has been shown to cause myocarditis, type 1 myocardial infarction (acute coronary syndrome and spontaneous coronary artery dissection), type 2 myocardial infarction, arrhythmias, microangiopathy, disseminated intravascular coagulation, systemic infection and cytokine storm [20-27].

COVID-19 COAGULATION DISORDERS AND BLEEDING

Studies have shown a link between SARS-CoV-2 and coagulopathy; however, the coagulopathy is distinct from that associated with sepsis associated disseminated intravascular coagulation (DIC) in that D-dimer levels are elevated, while platelet, fibrinogen and PT levels are normal. Increased risk
of death has been observed in coagulopathy associated with COVID-19.\textsuperscript{[29–42]}

**CARDIAC MANIFESTATIONS IN COVID-19**

Different mechanisms are involved in the pathogenesis of cardiac injury: microthrombosis is common and may persist even after clearing the virus. Myocarditis is usually very limited in extent while direct myocardial injury by the virus is not common. The immune response in COVID-19 infection is divided into two phases. The first occurs during the incubation stage of the disease, during which the adaptive immune system works to eliminate the virus; if for any reason, a defect occur at this stage, COVID-19 will disseminate and induce systemic organ damage, with more significant destruction of organs with higher expression of ACE2 receptors, including lung, endothelial cells, the heart, and the kidneys. This massive damage leads to phase 2: severe inflammation in the affected organs, which in case of heart damage, can lead to myocarditis with severely reduced ejection fraction.\textsuperscript{[43]} Cardiac troponin I levels were significantly higher in those with severe COVID-19–related symptoms compared with those with non-severe presentation.\textsuperscript{[44]} Myocardial injury, present in 19.7\% of COVID-19 patients, was associated with higher levels of inflammatory biomarkers, more severe pulmonary involvement, higher need for non-invasive and invasive ventilation and increased rates of acute respiratory distress syndrome, acute kidney injury, and coagulation disorders.\textsuperscript{[45]} Patients with myocardial injury were at higher risk of death.

COVID-19-induced cardiac injury is also via hyper-stimulation of the immune system/cytokine storm, which can lead to vascular endothelial injury as well as cardiac myocyte damage.\textsuperscript{[46]} Interleukin (IL)-2, IL-10, IL-6, IL-8, and tumor necrosis factor (TNF) are among the proinflammatory cytokines that are considerably increased in severe cases. Such uncontrolled immune system can lead to severe inflammation expressed by worsening preexisting plaques or promote accelerated atherogenesis.\textsuperscript{[47]} Because of this intense release of potent inflammatory cytokines, catecholamine surge, and microvascular injury, COVID-19 might cause stress cardiomyopathy (Takotsubo) and increases the vulnerability of preexisting plaques to rupture, leading to acute coronary syndrome.\textsuperscript{[48]}

**COVID-19 AND ACUTE CORONARY SYNDROME**

Several recent studies have reported the occurrence of Acute Coronary Syndromes in COVID-19 despite absence of demonstrable obstructive Coronary disease. In 28 Italian patients with ST-elevation myocardial infarction (STEMI) and COVID-19, Stefanini, et al.\textsuperscript{[49]} reported that STEMI represented the first clinical manifestation of COVID-19 in the majority of cases (85.7\%) with increased observed mortality was 39.3\%. In these patients, coronary angiography revealed the absence of obstructive coronary artery disease (CAD) in 39.3\% of cases, a finding also reported by Bangalore, et al.\textsuperscript{[50]} who found non-obstructive disease in one-third of the patients who underwent coronary angiography. In this latter series, the prognosis of STEMI presentation was worse than in the previous report, with a 72\% rate of in-hospital mortality. Microvascular thrombosis has also been hypothesized as a mechanism underlying certain cases mimicking presentation of STEMI without obstructive CAD, attributable to endothelial dysfunction and hypercoagulable state associated with COVID-19. Microvascular thrombosis was further investigated by Pellegriini, et al.\textsuperscript{[51]} who analyzed autopsies of 40 hearts from hospitalized patients who died due to COVID in Bergamo, Italy. They found that 14 hearts out of 40 had evidence of myocyte necrosis, mainly in the left ventricle. Nine out of these 14 hearts had microthrombi in myocardial arteries and capillaries. In comparison to intramyocardial thromboembolic material from COVID-19-negative patients with STEMI and aspirated thrombi from COVID-19 patients with STEMI during percutaneous cardiac intervention, microthrombi showed substantially more fibrin and terminal complement C5b-9 immunostaining.\textsuperscript{[51]}

**COVID-19 AND ARRYTHMIAS**

In addition to COVID-19, there are more than 20 viruses that have been linked to myocardial inflammation and myocarditis, with parvovirus B19, hu-
A survey organized by the Heart Rhythm Society showed that common arrhythmias in hospitalized patients with COVID are atrial fibrillation (21%), atrial flutter (5.4%), atrial tachycardia (3.5%), and paroxysmal supraventricular tachycardia (5.7%). Ventricular arrhythmias were also reported, the most common form was monomorphic premature ventricular contractions (5.3%). Regarding bradyarrhythmias in COVID-19 patients, sinus bradycardia and complete heart block were the most reported (8%) and (8%) respectively. First- or second-degree AV block, bundle branch block or intraventricular conduction delay were also reported. Guo, et al. showed that patients with underlying CVD exhibited elevated levels of troponin-T (TnT), which led to more frequent development of complications including malignant arrhythmias and ventricular tachycardia/fibrillation. Cardiac arrhythmias were two-fold more frequent at elevated Troponin levels.

In an Italian study, the rate of out-of-hospital cardiac arrests during the first 40 days of the COVID-19 epidemic was compared to the same period a year earlier. It was found out that there was a 58 percent rise in out-of-hospital cardiac arrests (362 arrests compared to 229 arrests in the previous year) throughout the research period, which was linked to the incidence of COVID-19. Out of all 362 cardiac arrests, COVID-19 was detected or suspected in 28% of the cases.

Furthermore, numerous medications used to treat COVID-19 infection, such as azithromycin and hydroxychloroquine, have been shown to cause arrhythmias. These medicines can raise the risk of arrhythmias including torsades de pointes and ventricular tachycardia secondary to prolongation of the QT interval.

COVID-19 AND HEART FAILURE

The occurrence of Heart failure in the context of COVID-19 infection is well recognized and is multifactorial. It can be the result of a direct effect of the virus on the myocardium or indirectly caused by supply and demand mismatch ischemia, volume overload, cytokine release, stress, renal failure, or overwhelming critical illness. COVID-19-induced acute coronary syndromes might lead to cardiac failure or aggravate pre-existing conditions.

COVID-19 patients may develop right-sided heart failure as a result of pulmonary involvement, hypoxia and acute respiratory distress syndrome. Right ventricular dilatation was found in 31% of intubated COVID-19 patients in a group of 105 patients hospitalized to Mount Sinai Morningside Hospital (New York, New York). Right ventricular hypokinesia was seen in 66% of COVID-19 patients with right ventricular enlargement vs. 5% of COVID-19 patients without right ventricular enlargement.

Bieber, et al. found that left ventricular dysfunction (both systolic and diastolic) and systolic right ventricular dysfunction occurred in 56 percent of their cohort (116 patients) and were more common in individuals with elevated troponin (88.8% vs. 14.3%, P < 0.001). Furthermore, this consequence occurs in the absence of a preexisting history of cardiovascular illness, indicating that COVID-19 has a direct role in the pathogenesis of heart failure. In COVID-19 patients, heart failure with preserved ejection fraction (HFpEF) is a frequent finding in terms of left ventricular dysfunction.
This finding might be explained by having a preexisting subclinical HFpEF or new diastolic dysfunction induced by systemic inflammation and hypoxia. Furthermore, HFpEF and COVID-19 appear to have a number of cardiometabolic risk factors in common, including obesity and older age. In the case of severe viral invasion, COVID-19 myocarditis can present as a cardiogenic shock. In a case report by Purdy, et al., they describe two patients, previously healthy, presenting with cardiogenic shock secondary to prolonged course of COVID. The two patients required treatment with steroids, inotropes, and diuretics before fully recovering 6 to 10 weeks later. One should also keep in mind that in the context of severe inflammatory response and cytokine storm, COVID-19 can present as distributive shock as well.

Biomarkers such as CRP, D dimers and troponin correlate with severity and mortality rates of COVID-19 related complications. A study conducted by Smilowitz, et al. involving 3281 consecutive adults hospitalized with COVID-19 showed that 2895 patients (88.2%) had measurements of all three biomarkers while only 196 patients (6.8%) had no elevated biomarkers.

COVID-19 VACCINE AND CARDIAC SIDE EFFECTS

A few cardiac manifestations have been attributed to COVID-19 vaccine. In a large study which assessed the cardiovascular adverse effects of COVID-19 vaccines from the WHO database, it was found that several vaccines are associated with cardiovascular adverse events. They include but are not limited to: hypertension, hypotension, palpitations, tachycardia, atrial fibrillation and flutter, angina pectoris, myocardial infarction and cardiac arrest. Although they remain rare compared to risk of developing such side effects from the infection itself, some unfortunate incidences were encountered following COVID-19 mRNA vaccination including myocarditis and STEMI.

REFERENCES

[1] Knobler S, Mahmoud A, Lemon S, et al. “Learning from SARS: Preparing for the Next Disease Outbreak: Workshop Summary”, (2004), Institute of Medicine (US) For-

um on Microbial Threats. National Academies Press: Washington (DC), USA.

[2] Al-Osail AM, Al-Wazzah MJ. The history and epidemiology of Middle East respiratory syndrome coronavirus. Multidiscip Respir Med 2017; 12: 20.

[3] Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 2020 16; 6: 14.

[4] Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433.

[5] Giovannetti M, Benvenuto D, Angeletti S, et al. The first two cases of 2019-nCoV in Italy: Where they come from? J Med Virol 2020; 92: 518–521.

[6] El Sayed M, Al Assad R, Abi Aad Y, et al. Measuring the impact of emergency medical services (EMS) on out-of-hospital cardiac arrest survival in a developing country: A key metric for EMS systems’ performance. Medicine (Baltimore) 2017; 96: e7570.

[7] Tesini BL. Coronaviruses and acute respiratory syndromes (COVID-19, MERS, and SARS). University of Rochester School of Medicine and Dentistry; 2020.

[8] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91: 157–160.

[9] Cheng VC, Lau SK, Woo PC, et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007; 20: 660–694.

[10] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513.

[11] Cowan LT, Lutsey PL, Pankow JS, et al. Inpatient and outpatient infection as a trigger of cardiovascular disease: the ARIC study. J Am Heart Assoc 2018; 7: e009683.

[12] Dhainaut JF, Claessens YE, Janes J, et al. Underlying disorders and their impact on the host response to infection. Clin Infect Dis 2005; 41 (Suppl 7): S481–S489.

[13] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062.

[14] Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015; 9: 217–237.

[15] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420–422.

[16] Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19. N Engl J Med 2020; 382: 1653–1659.

[17] Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020; 24: 422.

[18] Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 2007; 73: 463–469.

[19] Horiuichi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33: 613–621.
LETTER TO THE EDITOR

[20] Boukhris M, Hillani A, Moroni F, et al. Cardiovascular implications of the COVID-19 pandemic: a global perspective. Can J Cardiol 2020; 36: 1068–1080.

[21] Heurich A, Hofmann-Winkler H, Gierer S, et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 2014; 88: 1293–1307.

[22] Ruiz-Ortega M, Lorenzo O, Suzuki Y, et al. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10: 321–329.

[23] Yaghini FA, Song CY, Lavrentyev EN, et al. Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation. Hypertension 2010; 55: 1461–1467.

[24] Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005; 45: 163–169.

[25] Tummala PE, Chen XL, Sundell CL, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223–1229.

[26] Striker GE, Praddaude F, Alcazar O, et al. Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II. Am J Physiol Cell Physiol 2008; 295: C1633–C1646.

[27] Miesbach W. Pathological role of angiotensin II in severe COVID-19. TH Open 2020; 4: e138–e144.

[28] Belen-Apak FB, Saraioglu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thomb Thrombolysis 2020; 50: 278–280.

[29] Daughety MM, Morgan A, Frost E, et al. COVID-19 associated coagulopathy: thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Thromb Res 2020; 196: 483–485.

[30] Guan WJ, Ni ZY, Hu Y, et al. China medical treatment expert group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.

[31] Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844–847.

[32] Al-Samkari H, Karf Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136: 489–500.

[33] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.

[34] Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020; 142: 184–186.

[35] Refaat MM, Aouizerat BE, Pullinger CR, et al. Association of CASQ2 polymorphisms with sudden cardiac arrest and heart failure in patients with coronary artery disease. Heart Rhythm 2014; 11: 646–652.

[36] Khan M, Ibrahim RH, Siddiqi SA, et al. COVID-19 and acute ischemic stroke - A case series from Dubai, UAE. Int J Stroke 2020; 15: 699–700.

[37] Li JY, Wang HF, Yin P, et al. Thrombo-COVID-19 Collaborative. Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study. J Thromb Haemost 2021; 19: 1038–1048.

[38] McConagle D, O’Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020; 2: e437–e445.

[39] Thachil J. The versatile heparin in COVID-19. J Thromb Haemost 2020; 18: 1020–1022.

[40] Refaat MM, Hotait M, Tseng ZH. Utility of the exercise electrocardiogram testing in sudden cardiac death risk stratification. Ann Noninvasive Electrocardiol 2014; 19: 311–318.

[41] Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7: e438–e440.

[42] Zuo Y, Warnock M, Harbaugh A, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 2021; 11: 1580.

[43] Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020; 27: 1451–1454.

[44] Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis 2020; 63: 390–391.

[45] Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5: 802–810.

[46] Magadum A, Kishore R. Cardiovascular manifestations of COVID-19 infection. Cells 2020; 9: 2508.

[47] Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71: 762–768.

[48] Dominguez-Erquicia P, Dobarro D, Raposeiras-Roubin S, et al. Multivessel coronary thrombosis in a patient with COVID-19 pneumonia. Eur Heart J 2020; 41: 2132.

[49] Stefanini GG, Montorofano M, Trabattoni D, et al. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation 2020; 141: 2113–2116.

[50] Bangalore S, Sharma A, SLOTWINER A, et al. ST-segment elevation in patients with COVID-19-A Case Series. N Engl J Med 2020; 382: 2478–2480.

[51] Pellegrini D, Kawakami R, Guagliumi G, et al. Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. Circulation 2021; 143: 1031–1042.

[52] Gaalou I, Riabi S, Harrath R, et al. Sudden unexpected death related to enterovirus myocarditis: histopathology, immunohistochemistry and molecular pathology diagnosis at post-mortem. BMC Infect Dis 2012; 12: 212.

[53] Babapoor-Farrokhran S, Rasekhi RT, Gill D, et al. Arhythmia in COVID-19. SN Compr Clin Med 2020; 14: 1–6.
[54] Tse G, Yeo JM, Chan YW, et al. What is the arrhythmic substrate in viral myocarditis? insights from clinical and animal studies. Front Physiol 2016; 7: 308.

[55] Zhand S, Saghaeian Jazi M, Mohammadi S, et al. COVID-19: the immune responses and clinical therapy candidates. Int J Mol Sci 2020; 21: 5559.

[56] Sattar Y, Ullah W, Rauf H, et al. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. Int J Cardiol Heart Vasc 2020; 29: 100589.

[57] Kir D, Mohan C, Sancassani R. Heart brake: an unusual cardiac manifestation of COVID-19. JACC Case Rep 2020; 2: 1252–1255.

[58] Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5: 811–818.

[59] Gopinathannair R, Merchant FM, Lakireddy DR, et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol 2020; 59: 329–336.

[60] Baldi E, Sechi GM, Marc C, et al. Out-of-hospital cardiac arrest during the COVID-19 outbreak in Italy. N Engl J Med 2020; 383: 496–498.

[61] Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 2020; 17: 543–558.

[62] Argulian E, Sud K, Vogel B, et al. Right ventricular dilation in hospitalized patients with COVID-19 Infection. JACC Cardiovasc Imaging 2020; 13: 2459–2461.

[63] Bieber S, Kraechan A, Hellmuth JC, et al. Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury. Infection 2021; 49: 491–500.

[64] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091.

[65] Szekely Y, Lichter Y, Taieb P, et al. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation 2020; 142: 342–353.

[66] Ramadan MS, Bertolino L, Zampino R, et al. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. Clin Microbiol Infect 2021; S1198-743X(21)00335-9.

[67] Purdy A, Ido F, Sterner S, et al. Myocarditis in COVID-19 presenting with cardiogenic shock: a case series. Eur Heart J Case Rep 2021; 5: ytab028.

[68] Smilowitz NR, Nguy V, Aphinayanaphongs Y, et al. Multiple biomarker approach to risk stratification in COVID-19. Circulation 2021; 143: 1338–1340.

[69] Boivin Z, Martin J. Untimely myocardial infarction or COVID-19 Vaccine Side Effect. Cureus 2021; 13: e13651.

[70] Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem 2021; 36: 427–439.

[71] Albert E, Aurigemma G, Saucedo J, et al. Myocarditis following COVID-19 vaccination. Radiol Case Rep 2021; 16: 2142–2145.

[72] FDA Briefing Document: Moderna COVID-19 Vaccine. Vaccines and related biological products advisory committee meeting, https://www.fda.gov/media/144434/download (accessed on March 9, 2021).

Please cite this article as: Hatab T, Mounneh MB, Akkawi AR, Ghazal M, Alam SE, Refaat MM. COVID-19: cardiovascular manifestations—a review of the cardiac effects. J Geriatr Cardiol 2022; 19(3): 245–250. DOI: 10.11909/j.issn.1671-5411.2022.03.007